Owing to variable hypervascularity, immune cell infiltration, and PD-L1 expression in ccRCC, blocking the VEGF pathway and PD-L1 axis as a combination therapy has significantly prolonged the overall survival (OS) of patients with mRCC. The gene discussed is CD274; the disease is nonpapillary renal cell carcinoma.